派斯双林生物制药股份有限公司取得股票回购专项贷款承诺函公告
要点概览
- 公司已通过董事会决议，计划以集中竞价方式回购部分A股股份，总金额不低于2亿元、最高不超过3亿元人民币。
- 回购股份将全部用于员工持股计划或股权激励计划，回购价格上限为每股19.50元，回购期限最长为12个月。
- 公司已获得中国银行湛江分行出具的《贷款承诺函》，授信额度为2.7亿元人民币，授信期限为3年，专项用于回购股票。
- 贷款承诺函仅为融资支持，最终贷款以双方正式签署合同为准，实际回购数量以实际操作结果为准。
- 公司将根据相关规定，结合市场情况择机回购并及时披露进展。
对股东的影响与潜在价格敏感信息
- 回购方案的实施：股份回购通常会向市场传递公司对自身价值认可的信号，可能提升股价表现。
- 回购资金来源：公司不仅动用自有资金，还获得金融机构专项贷款承诺，显示公司融资能力强，增强回购方案的可执行性。
- 回购用途明确：全部用于员工持股计划或股权激励，有助于稳定和激励团队，长期有利于公司业绩。
- 风险提示：贷款承诺函并不等同于回购金额承诺，实际回购数量及进度取决于市场情况和公司决策；投资者需关注后续信息披露。
- 市场影响：该公告为重大事项，可能对公司股价产生积极影响，投资者需关注后续具体操作和市场反馈。
详细内容分析
派斯双林生物制药股份有限公司于2026年4月27日召开董事会，审议通过了以集中竞价方式回购股份的议案。此次回购资金规模为2亿至3亿元人民币，回购价格不高于19.50元/股，期限为12个月。股份回购后将全部用于员工持股计划或股权激励计划，有助于提升员工积极性，稳定核心团队。
为支持回购方案，公司近日获得中国银行湛江分行出具的《贷款承诺函》，授信额度为2.7亿元，约为回购所需资金总额的90%，授信期限3年，专项用于公司回购股票。这意味着公司在自有资金之外还拥有强有力的银行融资支持，增强回购计划的可操作性和灵活性。
需注意的是，贷款承诺函仅为融资支持，最终贷款以双方正式签署合同为准，实际回购数量将根据市场情况和公司决策确定。公司承诺将严格按照《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关规定实施，并及时披露回购进展。
此次股票回购方案及取得银行专项贷款承诺，显示公司对未来发展有信心，同时有助于提升公司股价和市场形象。建议投资者关注公司后续实施情况及信息披露，注意投资风险。
备查文件
- 中国银行湛江分行出具的《贷款承诺函》
免责声明
本文仅为信息披露分析，不构成任何投资建议。投资者需结合自身实际情况及市场风险谨慎决策，关注公司后续公告。
English version:
Pais Shuanglin Biopharma Co., Ltd. Obtains Special Loan Commitment Letter for Share Buyback
Key Highlights
- The company has approved a board resolution to repurchase part of its A-shares via centralized bidding, with a total amount not less than RMB 200 million and not more than RMB 300 million.
- All repurchased shares will be used for employee stock ownership plans or equity incentive schemes; buyback price capped at RMB 19.50 per share, buyback period up to 12 months.
- The company has obtained a loan commitment letter from Bank of China Zhanjiang Branch, with a credit line of RMB 270 million (90% of total buyback funds required), loan term of 3 years, specifically for stock buyback.
- The loan commitment letter is for financing support only; final loan depends on the formal contract, and actual buyback quantity depends on actual implementation.
- The company will strictly comply with relevant regulations and make timely disclosures based on progress and market conditions.
Shareholder Impact & Potential Price Sensitive Information
- Implementation of Buyback: Share buybacks often signal confidence in company value and may boost stock performance.
- Source of Buyback Funds: Company is using both internal funds and bank financing, demonstrating financial strength and enhancing feasibility.
- Clear Buyback Purpose: All repurchased shares will be used for employee incentives, which helps stabilize and motivate the team, benefiting long-term performance.
- Risk Warning: Loan commitment is not a guarantee of buyback amount; actual repurchase quantity and progress depend on market and company decisions. Investors should watch for further disclosures.
- Market Impact: This is a major event and may positively affect share price; investors should monitor actual operation and market reaction.
Detailed Content Analysis
Pais Shuanglin Biopharma’s board meeting on April 27, 2026, approved a centralized bidding share buyback plan, with funding scale of RMB 200–300 million, buyback price capped at RMB 19.50 per share, and a period of 12 months. All repurchased shares are for employee stock ownership or equity incentives, which should help motivate staff and stabilize the core team.
To support the buyback, the company received a loan commitment from Bank of China Zhanjiang Branch, with a credit line of RMB 270 million (about 90% of required funds), 3-year term, specifically for stock buyback. This shows strong financing capability and enhances the feasibility and flexibility of the buyback plan.
Note: The loan commitment is only for financing support; final loan is subject to contract, and actual buyback quantity will be determined by market conditions and company decisions. The company promises strict compliance with buyback regulations and timely disclosure of progress.
This buyback plan and obtaining special loan commitment demonstrate management’s confidence in future growth, and may improve share price and market image. Investors are advised to pay attention to implementation progress and risk disclosures.
Reference Documents
- Loan Commitment Letter from Bank of China Zhanjiang Branch
Disclaimer
This article is for information analysis only and does not constitute investment advice. Investors should make decisions based on their own circumstances and market risks, and follow subsequent company announcements.
